129 related articles for article (PubMed ID: 38194244)
1. Esketamine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder: A Retrospective Chart Review.
Alves-Pereira R; Fontes M; Cordeiro V; Bandeira ID; Faria-Guimarães D; Silva SS; Mello RP; Leal GC; Sampaio AS; Quarantini LC
Clin Neuropharmacol; 2024 Jan-Feb 01; 47(1):17-21. PubMed ID: 38194244
[TBL] [Abstract][Full Text] [Related]
2. Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder.
Dean RL; Hurducas C; Hawton K; Spyridi S; Cowen PJ; Hollingsworth S; Marquardt T; Barnes A; Smith R; McShane R; Turner EH; Cipriani A
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD011612. PubMed ID: 34510411
[TBL] [Abstract][Full Text] [Related]
3. Effects of ketamine in treatment-refractory obsessive-compulsive disorder.
Bloch MH; Wasylink S; Landeros-Weisenberger A; Panza KE; Billingslea E; Leckman JF; Krystal JH; Bhagwagar Z; Sanacora G; Pittenger C
Biol Psychiatry; 2012 Dec; 72(11):964-70. PubMed ID: 22784486
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.
Rodriguez CI; Kegeles LS; Levinson A; Feng T; Marcus SM; Vermes D; Flood P; Simpson HB
Neuropsychopharmacology; 2013 Nov; 38(12):2475-83. PubMed ID: 23783065
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.
Martinotti G; Chiappini S; Pettorruso M; Mosca A; Miuli A; Di Carlo F; D'Andrea G; Collevecchio R; Di Muzio I; Sensi SL; Di Giannantonio M
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34199023
[TBL] [Abstract][Full Text] [Related]
6. Comorbidity of obsessive-compulsive disorder and depression: prevalence, symptom severity, and treatment effect.
Overbeek T; Schruers K; Vermetten E; Griez E
J Clin Psychiatry; 2002 Dec; 63(12):1106-12. PubMed ID: 12523869
[TBL] [Abstract][Full Text] [Related]
7. The use of esketamine in comorbid treatment resistant depression and obsessive compulsive disorder following extensive pharmacogenomic testing: a case report.
Matteo M; Cristian P; Laura M; Federico M; Chiara R; Lorenzo G; Michaela K; Sibilla M; Roberto N; Fabrizia C; Antonios D; Alice C; Enrico C; Beatrice B; Francesca B; Nicoletta V; Alberto P; Silvia I; Massimo C
Ann Gen Psychiatry; 2021 Sep; 20(1):43. PubMed ID: 34530843
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted d-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Storch EA; Wilhelm S; Sprich S; Henin A; Micco J; Small BJ; McGuire J; Mutch PJ; Lewin AB; Murphy TK; Geller DA
JAMA Psychiatry; 2016 Aug; 73(8):779-88. PubMed ID: 27367832
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
[TBL] [Abstract][Full Text] [Related]
10. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review.
Bandeira ID; Lins-Silva DH; Cavenaghi VB; Dorea-Bandeira I; Faria-Guimarães D; Barouh JL; Jesus-Nunes AP; Beanes G; Souza LS; Leal GC; Sanacora G; Miguel EC; Sampaio AS; Quarantini LC
Harv Rev Psychiatry; 2022 Mar-Apr 01; 30(2):135-145. PubMed ID: 35267254
[TBL] [Abstract][Full Text] [Related]
11. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
Aboujaoude E; Barry JJ; Gamel N
J Clin Psychopharmacol; 2009 Feb; 29(1):51-5. PubMed ID: 19142108
[TBL] [Abstract][Full Text] [Related]
12. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.
Feusner JD; Kerwin L; Saxena S; Bystritsky A
Psychopharmacol Bull; 2009; 42(1):81-93. PubMed ID: 19204653
[TBL] [Abstract][Full Text] [Related]
13. Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder.
Niciu MJ; Grunschel BD; Corlett PR; Pittenger C; Bloch MH
J Psychopharmacol; 2013 Jul; 27(7):651-4. PubMed ID: 23676198
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of repeated intravenous ketamine treatment for resistant obsessive-compulsive disorder.
Sharma LP; Thamby A; Balachander S; Janardhanan CN; Jaisoorya TS; Arumugham SS; Reddy YCJ
Asian J Psychiatr; 2020 Aug; 52():102183. PubMed ID: 32554207
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
Tzavellas E; Karaiskos D; Ilias I; Liappas I; Paparrigopoulos T
Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
[TBL] [Abstract][Full Text] [Related]
16. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Jesus-Nunes AP; Leal GC; Correia-Melo FS; Vieira F; Mello RP; Caliman-Fontes AT; Echegaray MVF; Marback RF; Guerreiro-Costa LNF; Souza-Marques B; Santos-Lima C; Souza LS; Bandeira ID; Kapczinski F; Lacerda ALT; Quarantini LC
Hum Psychopharmacol; 2022 Jul; 37(4):e2836. PubMed ID: 35179810
[TBL] [Abstract][Full Text] [Related]
17. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
[TBL] [Abstract][Full Text] [Related]
18. The impact of trauma and post-traumatic stress disorder on the treatment response of patients with obsessive-compulsive disorder.
Shavitt RG; Valério C; Fossaluza V; da Silva EM; Cordeiro Q; Diniz JB; Belotto-Silva C; Cordioli AV; Mari J; Miguel EC
Eur Arch Psychiatry Clin Neurosci; 2010 Mar; 260(2):91-9. PubMed ID: 20077119
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review.
Ferguson AA; Khan AI; Abuzainah B; Chaudhuri D; Khan KI; Al Shouli R; Allakky A; Hamdan JA
Cureus; 2023 Apr; 15(4):e37833. PubMed ID: 37213965
[TBL] [Abstract][Full Text] [Related]
20. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC; Diniz JB; Requena G; Joaquim MA; Pittenger C; Bloch MH; Miguel EC; Shavitt RG
J Clin Psychiatry; 2017 Jul; 78(7):e766-e773. PubMed ID: 28617566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
